glucagon-like-peptide-1 and Pseudotumor-Cerebri

glucagon-like-peptide-1 has been researched along with Pseudotumor-Cerebri* in 1 studies

Other Studies

1 other study(ies) available for glucagon-like-peptide-1 and Pseudotumor-Cerebri

ArticleYear
Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension.
    The journal of headache and pain, 2023, Jul-18, Volume: 24, Issue:1

    In idiopathic intracranial hypertension (IIH), sustained weight loss is the main pillar in modifying disease course, whereby glucagon-like peptide-1 receptor agonists (GLP-1-RAs) could present an attractive treatment option.. In this open-label, single-center, case-control pilot study, patients with IIH (pwIIH) and a body mass index (BMI) of ≥ 30 kg/m. This open-label, single-center pilot study suggests that GLP-1-RAs are an effective and safe treatment option for achieving significant weight loss with a favorable effect on headache, leading to reduced acetazolamide dosage in pwIIH.

    Topics: Acetazolamide; Adult; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Headache; Humans; Male; Pilot Projects; Pseudotumor Cerebri; Weight Loss

2023